Key Takeaways
- Revenue doubled YoY, led by Ibuprofen and ARV recovery: Ibuprofen contributed ~18% of Q1 FY24 revenue and is in a launch take-off phase, while the ARV segment returned after being absent in FY23.
- Margins improved on mix and vertical integration: Operating margin rose on better product mix, new products, in-house intermediates, and improving Ibuprofen profitability.
- Ibuprofen ambition is bold but unproven: Management’s immediate plan is to make it “one of the largest in the world,” yet it declined to share market-share projections, citing incomplete approvals.
- ROCE target back-half loaded: Full-year ROCE is guided to 10–12%, with a Q4 exit rate of 15–17%, implying a steep ramp that depends on major products taking off.
- What to watch next quarter: Whether the Ibuprofen launch trajectory sustains its monthly volume climb, the durability of the ARV tender cycle, and any concrete progress on the vertical integration timeline.
Ibuprofen: The Big Bet
- Scale of contribution: Ibuprofen made up ~18% of Q1 FY24 revenue, with month-over-month and quarter-over-quarter improvement driven by new regulatory approvals and new market openings where customers are pulling the product.
- Launch phase dynamics: The company is in a “launch take-off phase,” shipping samples and securing approvals across diverse markets; management expects a clear picture of market position only by the end of FY24.
- Capacity discipline: No major capacity expansion is planned for FY24; the company will wait until existing utilization reaches 80–85% before adding, preferring to fill current capacity first.
- Market penetration challenge: The molecule is old and penetrating new markets is not easy; the company is pushing with available resources, but the process of diversifying the customer base and expanding into untapped regions typically takes 6–9 months.
Vamsi Krishna: “It's a process, it's a very age old molecule, where it's not very easy to penetrate into various markets where we are trying our level best to push it with the resources that we currently have.”
Segment Health & Recovery
| Segment | Trend | Commentary |
|---|---|---|
| Ibuprofen | ▲ Growing | Encouraging progress across all markets; monthly sales and volume uptick on new approvals. |
| ARV | ▲ Recovering | Absent in FY23, saw uptake in Q1 FY24; tender-based, good volumes expected for next couple of quarters. |
| Anti-diabetic | ▬ Stable | JV with Chemo; one of the largest exporters to Europe, collaboration expected to continue for next few quarters. |
| Antimigraine, Anti-ulcer, Anti-ED | ▬ Stable | Over two decades of presence; remarkable stability and devoted customer base. |
- ARV dependency risk: The business is contract manufacturing for large MNCs and entirely tender-based; volumes depend on partners winning tenders, and management finds it difficult to envision beyond 2–3 years.
- Therapeutic focus: New product development will concentrate on existing strong categories: anti-migraine, anti-ulcer, and HIV, rather than venturing into unfamiliar therapy areas.
Vamsi Krishna: “It's very difficult for us to you know envision how it's going to be in the next two - three years. But as of date it's the company for the next couple of quarters, I think we are envisioning good volumes on the ARV space as well.”
Margin & Return Profile
- Q1 margin drivers: Operating margin improvement came from product mix, new products, vertical integration (in-house intermediates for some products), and betterment of profits on Ibuprofen.
- ROCE trajectory: Full FY24 ROCE is expected at 10–12%, with a Q4 FY24 exit target of 15–17%, driven by product mix and good volumes of big products. The steep ramp depends on major products taking off in a “very good phase” by year-end.
- Raw material stability: China’s full reopening from COVID has stabilized prices; some pressure exists on solvent prices due to the ongoing war, but regular raw material prices remain stable.
Vamsi Krishna: “So it'll take time again, as I mentioned, right? So by end of this year, I think we will be in a very, very good position because that's when our major products will take off in a very good phase.”
Capital Allocation & R&D
- No major capex this year: No immediate Greenfield projects or major expansion; the focus is on consolidation and backward integration of critical, high-volume APIs.
- Capacity utilization gate: The company aims to fill current capacity to 75–80% before considering any fresh Greenfield projects or major expansion.
- R&D split: ~70% of the R&D budget is dedicated to cost/process improvements and backward integration of existing high-volume products; only ~30–35% goes to new product development.
- Vertical integration pipeline: Plans for the top five to six products have been chalked out and are already underway in development, with each product at various stages.
Vamsi Krishna: “around 70% of our R&D budget is dedicated to cost and process improvements of our existing products and towards backward integration of our existing high volume products and only around 30%, 35% we are looking at new product development.”
Market Focus & Geography
- Regulated markets priority: Major focus will be on regulated markets (US FDA and EUGMP-approved facilities) where profitability is higher; domestic contribution will also be high for high-volume products like Ibuprofen and Cetagliptin.
- New geography exploration: The company is exploring different geographies and establishing customer bases; registration is a long process, but incremental windfalls could be seen by end of FY24.
- No new product launches in Q1: No products were launched in the quarter; all existing products are performing well, and the company will add more products and explore different markets to increase revenue and profitability.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue & profit growth | 15–20% growth over FY23 in both top and bottom lines | FY24 |
| Operating margin | Sustained in line with present Q1 level | FY24 |
| ROCE | Full-year 10–12%; Q4 exit rate 15–17% | FY24 / Q4 FY24 |
| Ibuprofen market picture | Clear picture on market position and approvals | By end of FY24 |
| Capacity utilization | Fill current capacity to 75–80% before any Greenfield expansion | No date (condition-based) |
| Ibuprofen capacity expansion | Wait until existing capacity reaches 80–85% utilization | No date (condition-based) |
| ARV volumes | Good volumes expected | Next couple of quarters |
| Anti-diabetic collaboration | Expected to continue | Next few quarters |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| API segment revenue | ₹132.4 cr, 97.8% of consolidated revenue |
| Consolidated revenue growth guidance | 15% to 20% growth vs FY23, for full FY24 |
| EBITDA margin | 19.4%, vs 20+% in previous year |
| EBIT | ~₹19 cr (per an analyst's math) |
| ROCE | 18%+, expected 18% to 19% range for full FY24 |
| API export share | 85% of API segment revenue |
| API domestic share | 15% of API segment revenue |
| Ibuprofen revenue share | ~18% of total sales |
| Anti-diabetic revenue share | 24% of total sales |
| ARV revenue share | ~10% of total sales, projected 10% to 15% top-line contribution going forward |
| Anti-migraine revenue share | 19% of total sales |
| Anti-ulcer revenue share | 13% of total sales |
| Anti-inflammatory revenue share | 18% of total sales |
| Capacity utilization | 50% to 55%, target 75% to 80% before major expansion |
| Ibuprofen production capacity | ~700 metric tons per month, expandable to 1,200 metric tons per month |